Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer

Table 5 Association between initial metastatic or recurred sites and KRAS mutational status (N = 143) ^a

Initial metastatic or recurred site	WT KRAS	MT KRAS	Total N	P-value
	N (%)	N (%)
Liver				< 0.001
Yes	48 (70.6)	28 (37.3)	76
No	20 (29.4)	47 (62.7)	67
Lung				0.003
Yes	15 (22.1)	34 (45.3)	49
No	53 (77.9)	41 (54.7)	94
Distant lymph nodes				0.025
Yes	13 (19.1)	5 (6.7)	18
No	55 (80.9)	70 (93.3)	125
Peritoneum				0.451
Yes	17 (25.0)	23 (30.7)	40
No	51 (75.0)	52 (69.3)	103
Ovary^b				0.885
Yes	5 (7.4)	6 (8.0)	11
No	63 (92.6)	69 (92.0)	132

^a Initial metastatic or recurred sites were defined as the organs involved by distant metastasis at the time point of diagnosis of stage IV cancer (initial stage IV disease) or recurrence with distant metastasis (recurred cases from initial stage I-III disease). In these analyses, all enrolled cases (N = 143) were included.
^bAll cases who had Krukenberg tumors as the initial metastatic or recurred sites had peritoneal metastasis simultaneously. There were no cases with ovarian metastasis alone without peritoneal metastasis in our study.
Abbreviations: WT, wild-type; MT, mutant-type.

ISSN: 1471-2407